Chan-Tiopianco Mareesol, Chao Wei-Ting, Ching Patrick R, Jiang Ling-Yu, Wang Peng-Hui, Chen Yi-Jen
Division of Obstetrics and Gynecology, San Lazaro Hospital, Manila, PHL.
Department of Obstetrics and Gynecology, ManilaMed - Medical Center Manila, Manila, PHL.
Cureus. 2021 Jun 22;13(6):e15828. doi: 10.7759/cureus.15828. eCollection 2021 Jun.
This study aims to analyze the patient profile and presentation of endometriosis-related hemorrhagic ascites and review its management to raise awareness among gynecologists and improve treatment strategies. We present a case report and engage in a systematic review involving human cases of histologically proven endometriosis with hemorrhagic ascites. Keywords were searched in PubMed/MEDLINE, Cochrane Library, EMBASE, and Ovid Discovery databases from inception until December 2018. Studies that did not include a description of ascites or histopathologic results confirming endometriosis or those that involved patients with other conditions that may contribute to ascites were excluded. The review yielded 73 articles describing 84 premenopausal women with histologically proven endometriosis-related hemorrhagic ascites. Of note, 83% (65/78) of the patients were nulliparous and 69.35% (43/62) were of African descent. The most common chief complaint was abdominal enlargement (58.33%, 49/84) but a host of other symptoms were also reported. Pleural effusion was reported in 32.14% (27/84), and elevated CA-125 was seen in 74.42% (32/43). The majority (64.29%, 54/84) of the patients underwent laparotomy, and an increasing trend of minimally invasive surgical approaches (p<0.001) and fertility-sparing techniques (p<0.001) was observed. The mean ascites volume was 4228.27 mL (SD: 2625.66). Moderate to severe endometriosis was seen in 97.44% (76/78) of cases. The majority of the patients who received medical treatment were given gonadotropin-releasing hormone (GnRH) agonists (63.79%, 37/58). The rate of recurrence after termination or suppression of ovarian function was 8.33% (7/84), and there was a mortality rate of 1.19% (1/84). Diagnosis of endometriosis-related hemorrhagic ascites may be challenging because it mimics several disease entities that cause ascites, thereby warranting a heightened clinical suspicion. Minimally invasive techniques are usually employed to establish a histologic diagnosis. The prevention of recurrence involves the recognition of endometriosis-related hemorrhagic ascites as a manifestation of severe endometriosis, which should prompt therapies directed at suppressing ovarian function. Since affected women are of childbearing age, ovary-preserving surgeries are generally preferred. The rate of recurrence is low after appropriate surgical and medical interventions.
本研究旨在分析子宫内膜异位症相关出血性腹水的患者特征和临床表现,并回顾其治疗方法,以提高妇科医生的认识并改进治疗策略。我们报告一例病例,并对经组织学证实为子宫内膜异位症伴出血性腹水的人类病例进行系统综述。从数据库建立至2018年12月,在PubMed/MEDLINE、Cochrane图书馆、EMBASE和Ovid Discovery数据库中检索关键词。排除未包括腹水描述或未证实子宫内膜异位症的组织病理学结果的研究,以及涉及可能导致腹水的其他疾病患者的研究。该综述共纳入73篇文章,描述了84例绝经前经组织学证实为子宫内膜异位症相关出血性腹水的女性患者。值得注意的是,83%(65/78)的患者未生育,69.35%(43/62)为非洲裔。最常见的主要症状是腹部膨隆(58.33%,49/84),但也报告了许多其他症状。32.14%(27/84)的患者报告有胸腔积液,74.42%(32/43)的患者CA-125升高。大多数患者(64.29%,54/84)接受了剖腹手术,且观察到微创外科手术方法(p<0.001)和保留生育功能技术(p<0.001)呈上升趋势。平均腹水量为4228.27 mL(标准差:2625.66)。97.44%(76/78)的病例为中重度子宫内膜异位症。大多数接受药物治疗的患者使用了促性腺激素释放激素(GnRH)激动剂(63.79%,37/58)。卵巢功能终止或抑制后的复发率为8.33%(7/84),死亡率为1.19%(1/84)。子宫内膜异位症相关出血性腹水的诊断可能具有挑战性,因为它可模仿多种导致腹水的疾病实体,因此需要提高临床怀疑度。通常采用微创技术进行组织学诊断。预防复发包括认识到子宫内膜异位症相关出血性腹水是重度子宫内膜异位症的一种表现,这应促使采取抑制卵巢功能的治疗方法。由于受影响的女性处于生育年龄,一般首选保留卵巢的手术。经过适当的手术和药物干预后,复发率较低。